Orchestra BioMed CEO RSU tax withholding of 3,283 OBIO shares

Orchestra BioMed Holdings, Inc. insider filing reports a tax-related share withholding by a senior executive.

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. insider filing reports a tax-related share withholding by a senior executive. On 11/13/2025, the Chief Executive Officer and Chairperson had 3,283 shares of common stock withheld by the company at a price of $4.18 per share to cover tax obligations arising from the vesting of restricted stock units. The filing states that no shares were sold in the market as a result of this vesting and related tax withholding. Following this transaction, the reporting person beneficially owns 607,822 shares directly and 442,765 shares indirectly through the DPH 2008 Trust.

Insider Trade Summary

Exercise Price or Tax Liability: 6,566 shares

Exercise Price or Tax Liability 2 txns

Insider Hochman David P

Role See Remarks

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock, par value $0.0001 per share ("Common Stock")	3,283	$4.18	$14K
Exercise Price or Tax Liability	Common Stock	3,283	$4.18	$14K

Holdings After Transaction: Common Stock, par value $0.0001 per share ("Common Stock") — 607,822 shares (Direct); Common Stock — 442,765 shares (Indirect, By the DPH 2008 Trust)

Footnotes (1)

1. F1. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OBIO report in this Form 4?

The Form 4 reports that on 11/13/2025, an executive of Orchestra BioMed Holdings, Inc. (OBIO) had 3,283 shares of common stock withheld by the company to satisfy tax withholding obligations related to vesting restricted stock units.

Were any OBIO shares sold in the market in this transaction?

No. The filing explains that the 3,283 shares were withheld by the issuer to satisfy tax obligations from restricted stock unit vesting and that no shares were sold in the market as a result.

How many OBIO shares does the reporting person own after the transaction?

After the transaction, the reporting person beneficially owns 607,822 shares of OBIO common stock directly and 442,765 shares indirectly through the DPH 2008 Trust.

What was the price used for the OBIO tax withholding shares?

The shares withheld to cover taxes were valued at $4.18 per share of Orchestra BioMed Holdings, Inc. common stock.

What is the role of the reporting person at Orchestra BioMed Holdings, Inc.?

The reporting person is identified as both Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc., and is also listed as a Director.

Is this OBIO Form 4 filed by one person or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, not by more than one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hochman David P

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	11/13/2025		F(1)		3,283	D	$4.18	607,822	D
Common Stock	11/13/2025		F(1)		3,283	D	$4.18	442,765	I	By the DPH 2008 Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations.

Remarks:

Chief Executive Officer and Chairperson

	/s/ Andrew Taylor, Attorney-in-Fact	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.